Coccidioidomycosis Pneumonia in a Nonendemic Area Associated with Infliximab
Authors:
- Bruce A. BaethgeBBBruce A. Baethge
- Alexander G. DuarteADAlexander G. Duarte
- 1 May 2007
- journal article
- case report
- Published by Southern Medical Association in Southern Medical Journal
- Vol. 100 (5) , 517-518
Abstract
Tumor necrosis factor (TNF) inhibitors, such as infliximab, are highly effective in the management of rheumatoid arthritis; however, these agents are associated with an increased risk of infectious complications. Individuals developing coccidiomycosis pneumonia frequently acquire this while residing in endemic regions. We present a patient with rheumatoid arthritis treated with infliximab who...Keywords
This publication has 7 references indexed in Scilit:
- Immunosuppression Related to Collagen-Vascular Disease or Its TreatmentProceedings of the American Thoracic Society, 2005
- Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonistsArthritis & Rheumatism, 2005
- The Benefit/Risk Profile of TNF-Blocking Agents: Findings of a Consensus PanelSeminars in Arthritis and Rheumatism, 2005
- Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonistsArthritis & Rheumatism, 2004
- Histoplasmosis after Treatment with Anti–Tumor Necrosis Factor-α TherapyAmerican Journal of Respiratory and Critical Care Medicine, 2003
- CoccidioidomycosisInfectious Disease Clinics of North America, 2003
- Coccidioidomycosis in non-endemic areas: a case seriesRespiratory Medicine, 2001